Quality of life
OA
Overall, patients in the SPMs group showed improvements in all five dimensions of the EUROQoL-5 compared to the placebo group, including significant changes in the usual activities dimension (52.17% vs. 14.29%; p-value = 0.004) (Table Quality of life in OA patients (N = 51)Percentage change in each patient has been used to calculate the mean score change. EQ VAS: EuroQol Visual Analogue Scale; SPMs: specialized pro-resolving lipid mediators